Open Access. Powered by Scholars. Published by Universities.®
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Autism Spectrum Disorder (3)
- Congenital Heart Defects (3)
- COVID-19 (2)
- Case Reports (2)
- Eclampsia (2)
-
- Female (2)
- Humans (2)
- Infant (2)
- Male (2)
- Middle Aged (2)
- Neurodevelopmental Disorders (2)
- Neurodivergent (2)
- Pain Management (2)
- Pre-Eclampsia (2)
- Thrombocytopenia (2)
- Ultrasound (2)
- 3rd level students (1)
- 80 and over (1)
- ADAMTS13 Protein (1)
- AHUS (1)
- ASD (1)
- Abdomen (1)
- Abdominal Radiography (1)
- Abnormal gait pattern (1)
- Acute Pain (1)
- Adult (1)
- Aged (1)
- Aged, 80 and over (1)
- Alzheimer Disease (1)
- Alzheimer's (1)
- Publication
- Publication Type
- File Type
Articles 31 - 31 of 31
Full-Text Articles in Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Evaluating Cognition In Individuals With Huntington Disease: Neuroqol Cognitive Functioning Measures, Jin-Shei Lai, Siera Goodnight, Nancy R Downing, Rebecca E Ready, Jane S Paulsen, Anna L Kratz, Julie C Stout, Michael K Mccormack, David Cella, Christopher Ross, Jenna Russell, Noelle E Carlozzi
Evaluating Cognition In Individuals With Huntington Disease: Neuroqol Cognitive Functioning Measures, Jin-Shei Lai, Siera Goodnight, Nancy R Downing, Rebecca E Ready, Jane S Paulsen, Anna L Kratz, Julie C Stout, Michael K Mccormack, David Cella, Christopher Ross, Jenna Russell, Noelle E Carlozzi
Rowan-Virtua School of Osteopathic Medicine Departmental Research
PURPOSE: Cognitive functioning impacts health-related quality of life (HRQOL) for individuals with Huntington disease (HD). The Neuro-QoL includes two patient-reported outcome (PRO) measures of cognition-Executive Function (EF) and General Concerns (GC). These measures have not previously been validated for use in HD. The purpose of this analysis is to evaluate the reliability and validity of the Neuro-QoL Cognitive Function measures for use in HD.
METHODS: Five hundred ten individuals with prodromal or manifest HD completed the Neuro-QoL Cognition measures, two other PRO measures of HRQOL (WHODAS 2.0 and EQ5D), and a depression measure (PROMIS Depression). Measures of functioning The Total …